These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 22852027)

  • 1. Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born.
    Schweizer MT; Antonarakis ES
    Ther Adv Urol; 2012 Aug; 4(4):167-78. PubMed ID: 22852027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agents that target androgen synthesis in castration-resistant prostate cancer.
    Ferraldeschi R; de Bono J
    Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].
    Neuzillet Y; Flamand V; Lebdai S; Villers A; Lebret T
    Prog Urol; 2013 Oct; 23 Suppl 1():S34-43. PubMed ID: 24314737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.
    Rehman Y; Rosenberg JE
    Drug Des Devel Ther; 2012; 6():13-8. PubMed ID: 22291466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abiraterone in the treatment of metastatic castration-resistant prostate cancer.
    Mostaghel EA
    Cancer Manag Res; 2014; 6():39-51. PubMed ID: 24501545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions.
    Leibowitz-Amit R; Joshua AM
    Curr Oncol; 2012 Dec; 19(Suppl 3):S22-31. PubMed ID: 23355790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Castrate-resistant prostate cancer: postdocetaxel management.
    Zhao S; Yu EY
    Curr Opin Urol; 2013 May; 23(3):201-7. PubMed ID: 23344012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions.
    Bedoya DJ; Mitsiades N
    Onco Targets Ther; 2013; 6():9-18. PubMed ID: 23319868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Treatment Patterns in Patients with Castrate-Resistant Prostate Cancer and Bone Metastases.
    Wen L; Valderrama A; Costantino ME; Simmons S
    Am Health Drug Benefits; 2019 May; 12(3):142-149. PubMed ID: 31346366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis.
    Perletti G; Monti E; Marras E; Cleves A; Magri V; Trinchieri A; Rennie PS
    Arch Ital Urol Androl; 2015 Jul; 87(2):121-9. PubMed ID: 26150028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress in emerging therapies for advanced prostate cancer.
    Oudard S
    Cancer Treat Rev; 2013 May; 39(3):275-89. PubMed ID: 23107383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New agents for prostate cancer.
    Agarwal N; Di Lorenzo G; Sonpavde G; Bellmunt J
    Ann Oncol; 2014 Sep; 25(9):1700-1709. PubMed ID: 24658665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer.
    Semenas J; Dizeyi N; Persson JL
    Drug Des Devel Ther; 2013; 7():875-81. PubMed ID: 24009414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies.
    Kim W; Ryan CJ
    Cancer; 2015 Feb; 121(3):361-71. PubMed ID: 25236176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate Cancer.
    McKay RR; Werner L; Fiorillo M; Roberts J; Heath EI; Bubley GJ; Montgomery RB; Taplin ME
    Clin Genitourin Cancer; 2017 Aug; 15(4):463-471. PubMed ID: 27890446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Castration-resistant prostate cancer: novel therapeutics pre- or post- taxane administration.
    Shiota M; Yokomizo A; Fujimoto N; Kuruma H; Naito S
    Curr Cancer Drug Targets; 2013 May; 13(4):444-59. PubMed ID: 23517595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
    Al Nakouzi N; Le Moulec S; Albigès L; Wang C; Beuzeboc P; Gross-Goupil M; de La Motte Rouge T; Guillot A; Gajda D; Massard C; Gleave M; Fizazi K; Loriot Y
    Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.